Ryanair Holdings plc vs GeneDx Holdings Corp — how do they compare? Ryanair Holdings plc trades at $58.99 (market cap $29.31B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Ryanair Holdings plc is far larger — about 16.3× GeneDx Holdings Corp's market cap, and Ryanair Holdings plc pays a 1.68% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| RYAAY | WGS | |
|---|---|---|
Market Cap | $29.31B | $1.80B |
Sector | Industrials | Technology |
52-Week High | $73.82 | $167.51 |
52-Week Low | $53.24 | $34.51 |
Enterprise Value | $26.33B | $1.80B |
Dividend Yield | 1.68% | — |
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $58.80, down 6.03% amid a bearish technical signal. Recent Q1 2027 earnings missed expectations due to lower fares and higher fuel costs, though the company maintains strong profitability with a 13.98% net margin. Analyst consensus remains positive with 62.5% buy ratings, citing long-term advantages despite near-term headwinds from geopolitical tensions and industry volatility.
The outlook is cautious short-term given earnings pressure and technical weakness, but the strong balance sheet and potential industry consolidation offer recovery potential. Key risks include fuel price volatility and competitive fare pressures, while institutional sentiment suggests the sell-off may be overdone for value-oriented investors.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →